Compare Stocks: TRML, LQDA, INDV, and ARQT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$32.00 +2.4%	$26.78	$19.30 ▼ $33.30	$4.02B	1.57	1.83 million shs	1.62 million shs
INDV Indivior	$36.40 +0.3%	$35.19	$27.68 ▼ $42.81	$4.30B	0.87	2.50 million shs	3.65 million shs
LQDA Liquidia	$42.20 +0.8%	$52.46	$22.31 ▼ $93.61	$3.78B	0.61	2.28 million shs	2.18 million shs
TRML Tourmaline Bio	$47.98	$47.95	$13.27 ▼ $48.27	$1.23B	2.27	592,710 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-2.53%	-1.73%	+24.24%	+20.09%	+23.51%
INDV Indivior	+2.57%	+4.98%	+1.60%	-0.60%	+23.53%
LQDA Liquidia	-7.12%	-4.32%	+46.12%	-52.65%	+71.80%
TRML Tourmaline Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$32.00 +2.4%	$26.78	$19.30 ▼ $33.30	$4.02B	1.57	1.83 million shs	1.62 million shs
INDV Indivior	$36.40 +0.3%	$35.19	$27.68 ▼ $42.81	$4.30B	0.87	2.50 million shs	3.65 million shs
LQDA Liquidia	$42.20 +0.8%	$52.46	$22.31 ▼ $93.61	$3.78B	0.61	2.28 million shs	2.18 million shs
TRML Tourmaline Bio	$47.98	$47.95	$13.27 ▼ $48.27	$1.23B	2.27	592,710 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-2.53%	-1.73%	+24.24%	+20.09%	+23.51%
INDV Indivior	+2.57%	+4.98%	+1.60%	-0.60%	+23.53%
LQDA Liquidia	-7.12%	-4.32%	+46.12%	-52.65%	+71.80%
TRML Tourmaline Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.80	Moderate Buy	$39.13	22.27% Upside
INDV Indivior	3.00	Buy	$46.40	27.47% Upside
LQDA Liquidia	2.42	Hold	$72.85	72.62% Upside
TRML Tourmaline Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRML, LQDA, INDV, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/29/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
10/28/2026	INDV Indivior	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$43.00 ➝ $45.00
10/19/2026	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$38.00 ➝ $44.00
10/15/2026	LQDA Liquidia	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$65.00
10/15/2026	ARQT Arcutis Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$48.00
10/15/2026	LQDA Liquidia	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$58.00 ➝ $65.00
10/14/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C) ➝ Hold (C-)
10/14/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$30.00 ➝ $33.00
10/14/2026	LQDA Liquidia	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Outperform	$59.00
10/14/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$70.00
10/14/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$72.00 ➝ $58.00

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$463.98M	8.67	N/A	N/A	$1.55 per share	20.65
INDV Indivior	$1.37B	3.13	$2.85 per share	12.78	($0.78) per share	-46.67
LQDA Liquidia	$158.32M	23.86	N/A	N/A	$0.51 per share	82.75
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	152.39	30.19	N/A	6.15%	15.05%	6.51%	11/4/2026 (Estimated)
INDV Indivior	$210M	$3.58	10.17	9.50	N/A	26.65%	-283.11%	36.85%	N/A
LQDA Liquidia	-$68.92M	$1.37	30.80	19.81	0.40	30.74%	149.65%	36.30%	N/A
TRML Tourmaline Bio	-$73.21M	-$3.43	N/A	N/A	N/A	N/A	-30.50%	-29.63%	N/A

Latest TRML, LQDA, INDV, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	ARQT Arcutis Biotherapeutics	$0.18	N/A	N/A	N/A	$142.59 million	N/A
10/29/2026	Q3 2026	INDV Indivior	$1.06	$1.32	+$0.26	$1.12	$329.35 million	$356.00 million
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Latest TRML, LQDA, INDV, and ARQT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/16/2026	INDV Indivior	special	$8.13		11/3/2026	10/30/2026	11/6/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
INDV Indivior	N/A	0.84	0.66
LQDA Liquidia	0.63	2.31	2.12
TRML Tourmaline Bio	N/A	24.68	24.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
INDV Indivior	60.33%
LQDA Liquidia	64.54%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
INDV Indivior	0.74%
LQDA Liquidia	25.60%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
INDV Indivior	838	118.03 million	117.16 million	Optionable
LQDA Liquidia	216	89.51 million	66.60 million	Optionable
TRML Tourmaline Bio	44	25.69 million	22.35 million	Optionable

TRML, LQDA, INDV, and ARQT Headlines

Recent News About These Companies

Tourmaline Bio acquisition completed by Novartis

October 28, 2025 | msn.com

Novartis announces expiration of Tourmaline Bio tender offer

October 28, 2025 | msn.com

Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML

October 6, 2025 | businesswire.com

Tourmaline Bio (TRML) Price Target Decreased by 14.70% to 48.90

September 30, 2025 | msn.com

Novartis announces commencement of tender offer to acquire Tourmaline Bio

September 29, 2025 | globenewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)

September 15, 2025 | prnewswire.com

BMO Capital Downgrades Tourmaline Bio (TRML)

September 15, 2025 | msn.com

Tourmaline Bio (TRML): Assessing Valuation as Market Interest Grows

September 14, 2025 | finance.yahoo.com

Tourmaline Bio Updates Executive Severance Plan

September 12, 2025 | tipranks.com

Piper Sandler Downgrades Tourmaline Bio (TRML)

September 12, 2025 | msn.com

TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc ...

September 11, 2025 | tmcnet.com

TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML

September 11, 2025 | businesswire.com

Guggenheim Downgrades Tourmaline Bio (TRML)

September 11, 2025 | msn.com

HC Wainwright & Co. Downgrades Tourmaline Bio (TRML)

September 10, 2025 | msn.com

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

September 10, 2025 | zacks.com

LifeSci Capital Downgrades Tourmaline Bio (TRML)

September 10, 2025 | msn.com

This Small Biotech Stock Is Surging Today. Here's Why.

September 9, 2025 | investopedia.com

Novartis to acquire Tourmaline Bio for $1.4 billion

September 9, 2025 | msn.com

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

September 9, 2025 | finance.yahoo.com

TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders

September 9, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRML, LQDA, INDV, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$32.00 +0.74 (+2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$31.96 -0.04 (-0.11%)

As of 07:36 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Indivior NASDAQ:INDV

$36.40 +0.12 (+0.33%)

Closing price 11/2/2026 07:30 PM Eastern

Extended Trading

$36.40 0.00 (0.00%)

As of 11/2/2026 07:30 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Liquidia NASDAQ:LQDA

$42.20 +0.35 (+0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$42.22 +0.02 (+0.04%)

As of 07:53 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Tourmaline Bio NASDAQ:TRML

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRML, LQDA, INDV, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRML, LQDA, INDV, and ARQT Earnings

Compare Dividends

Latest TRML, LQDA, INDV, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRML, LQDA, INDV, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRML, LQDA, INDV, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Indivior NASDAQ:INDV

Liquidia NASDAQ:LQDA

Tourmaline Bio NASDAQ:TRML

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRML, LQDA, INDV, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRML, LQDA, INDV, and ARQT Earnings

Compare Dividends

Latest TRML, LQDA, INDV, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRML, LQDA, INDV, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRML, LQDA, INDV, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Indivior NASDAQ:INDV

Liquidia NASDAQ:LQDA

Tourmaline Bio NASDAQ:TRML

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools